IMS Health Revenue and Competitors

Danbury, CT USA

Location

$3.5B

Total Funding

Estimated Revenue & Valuation

  • IMS Health's estimated annual revenue is currently $58.9M per year.(i)
  • 0
  • IMS Health's total funding is $3.5B.

Employee Data

    00

IMS Health's People

NameTitleEmail/Phone
1
Director, Payer SolutionsReveal Email/Phone
2
Director PricingReveal Email/Phone
3
General Manager Marketing & CommunicationsReveal Email/Phone
4
Chairman/CEOReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$22.7M84-26%N/AN/A
#2
$9.3M438%N/AN/A
#3
$18.2M751%N/AN/A
#4
$16.3M6749%N/AN/A
#5
$42.8M1447%N/AN/A
#6
$17.5M729%N/AN/A
#7
$27.5M10211%N/AN/A
#8
$8.9M4111%N/AN/A
#9
$27.8M1034%N/AN/A
#10
$9.7M452%N/AN/A
Add Company

What Is IMS Health?

A new company built from a foundation of deep experience and capabilities. We’re designing our approach to help our clients move healthcare forward. New ways to improve clinical trials. More robust evidence to support treatments. A clearer picture of the patient journey. Insights that actually lead to better commercial performance.

keywords:N/A

$3.5B

Total Funding

N/A

Number of Employees

$58.9M

Revenue (est)

N/A

Employee Growth %

N/A

Valuation

N/A

Accelerator

IMS Health News

2022-04-20 - Cegedim: 2022 off to a promising start

Given the current geopolitical and public health backdrop, ... Cegedim, jointly with IQVIA (formerly IMS Health), is being sued by Euris for...

2022-04-17 - Multinational healthcare services company agrees to pay ...

MOUNTAINSIDE, NJ – IQVIA Inc., a multinational healthcare ... In November 2017, Quintiles and IMS Health Inc., merged to form IQVIA.

2022-04-13 - Medicx Health Is Expanding New Analytics Unit Talent

SCOTTSDALE, Ariz., April 21, 2022 /PRNewswire/ -- Medicx Health is ... Janssen/J&J, IBM, IMS Health/IQVIA and NDCHealth/Symphony Health.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$0.3M20%N/A
#2
$0.2M3-25%N/A
#3
$0.2M30%N/A
#4
$0.4M6N/AN/A
#5
$0.6M740%N/A